Browse > Article
http://dx.doi.org/10.3904/kjm.2014.87.3.357

A Case of Prolonged Hypogammaglobulinemia after Rituximab-Containing Chemotherapy in a Patient with Lymphoma  

Noh, Hyun Jin (Departments of Internal Medicine, The Catholic University of Korea College of Medicine)
Gong, Bong Han (Departments of Internal Medicine, The Catholic University of Korea College of Medicine)
Kim, Young Sin (Departments of Internal Medicine, The Catholic University of Korea College of Medicine)
Jung, Yun Hwa (Departments of Internal Medicine, The Catholic University of Korea College of Medicine)
Woo, In Sook (Departments of Internal Medicine, The Catholic University of Korea College of Medicine)
Han, Chi Wha (Departments of Internal Medicine, The Catholic University of Korea College of Medicine)
Publication Information
The Korean Journal of Medicine / v.87, no.3, 2014 , pp. 357-362 More about this Journal
Abstract
Rituximab, an anti-CD20 monoclonal antibody, is an effective target agent against the B lymphocytes in B-cell lymphoid malignancies and various lymphoproliferative diseases. Moreover, the toxicity of rituximab is less severe than that of conventional cytotoxic agents, which has promoted the widespread application of rituximab in the treatment of B-cell lymphoma. However, depletion of B lymphocytes by rituximab, which leads to secondary hypogammaglobulinemia, can cause deterioration of humoral immunity. Although immune reconstitution after hematopoietic stem cell transplantation is known to prevent prolonged hypogammaglobulinemia, very few cases of long-standing hypogammaglobulinemia have been reported. We report herein a case of prolonged hypogammaglobulinemia after rituximab-containing chemotherapy and splenectomy in a patient with non-Hodgkin's lymphoma and discuss the clinical significance and pathogenetic mechanism of this phenomenon with a literature review.
Keywords
Non-Hodgkin's lymphoma; Rituximab; IgG deficiency;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hicks LK, Woods A, Buckstein R, et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009;43:701-708.   DOI   ScienceOn
2 Kurokawa T, Hase M, Tokuman N, Yoshida T. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol 2011;29:5-9.   DOI   ScienceOn
3 Abulayha AM, Tabal SA, Shawesh EI, et al. Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma. Leuk Res 2010;34:307-311.   DOI   ScienceOn
4 Nishio M, Endo T, Fujimoto K, et al. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol 2009;82:143-147.   DOI   ScienceOn
5 Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM memory B cells? Immunol Lett 2013;152:114-120.   DOI   ScienceOn
6 Walker AR, Kleiner A, Rich L, et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 2008;26:431-433.   DOI   ScienceOn
7 Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013;13:106-111.   DOI   ScienceOn
8 Walewski J, Kraszewska E, Mioduszewska O, et al. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol 2001;18:141-148.   DOI   ScienceOn
9 Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007;122:139-145.   DOI   ScienceOn
10 Avanzini MA, Locatelli F, Dos Santos C, et al. B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Exp Hematol 2005;33:480-486.   DOI   ScienceOn